Kai Wermker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai Wermker has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Johannes Kleinheinz
University Hospital Münster, Department of Cranio-Maxillofacial Surgery, Waldeyerstraße 30, 48149, Muenster, Germany
8 shared publications- Frank Hölzle
Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, 52074 Aachen, Germany
7 shared publications J. Kleinheinz
7 shared publications- Maurice Klein
Department of Oral & Maxillofacial Surgery, School of Medicine, University Hospital RWTH Aachen, Aachen, Germany
7 shared publications U. Joos
7 shared publications- Johannes Kleinheinz
Department of Cranio-Maxillofacial Surgery, University of Münster, 48149 Münster, Germany
6 shared publications
Latest Publications
- 12 October 2026
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 19 (4) , 287-302
Maligne Tumoren der Gesichtshaut: Therapie und Outcome
- 12 October 2026
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 19 (4) , 287-302
Maligne Tumoren der Gesichtshaut: Therapie und Outcome
- Open Access
- 14 September 2026
- Published by Elsevier in Archives of Oral Biology
- Vol. 192, 106765
A potential new biomarker in lip cancer: Metastasis suppressor protein 1 (MTSS1)
- 14 September 2026
- Published by Elsevier in Archives of Oral Biology
- Vol. 192, 106765
Open AccessA potential new biomarker in lip cancer: Metastasis suppressor protein 1 (MTSS1)
- 12 August 2026
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 19 (3) , 207-215
Maligne Tumoren der Gesichtshaut: Epidemiologie, Klassifikation und Diagnostik
- 12 August 2026
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 19 (3) , 207-215
Maligne Tumoren der Gesichtshaut: Epidemiologie, Klassifikation und Diagnostik
- Open Access
- 10 August 2026
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 54 (10)
Relative tumour budding (TB rel) predicts occult nodal metastasis, aggressiveness and survival in oral squamous cell carcinoma
- 10 August 2026
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 54 (10)
Open AccessRelative tumour budding (TB rel) predicts occult nodal metastasis, aggressiveness and survival in oral squamous cell carcinoma
- 5 December 2025
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 18 (4) , 229-230
Quo Vadis DGMKG? Rückblick und Ausblick
- 5 December 2025
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 18 (4) , 229-230
Quo Vadis DGMKG? Rückblick und Ausblick
- 30 October 2025
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 18 (4) , 254-260
Blick nach vorn – Risiken, Herausforderungen und Chancen aus Sicht nichtuniversitärer MKG-chirurgischer Abteilungen
- 30 October 2025
- Published by Springer Nature in Die MKG-Chirurgie
- Vol. 18 (4) , 254-260
Blick nach vorn – Risiken, Herausforderungen und Chancen aus Sicht nichtuniversitärer MKG-chirurgischer Abteilungen
- Open Access
- 18 July 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (7) , 560
Next-Generation Sequencing Reveals the Potential Role of RET Protooncogene in Metastasis Progression in Medullary Thyroid Cancer
Background: Medullary thyroid carcinoma (MTC) has a high rate of local and distant metastases. In particular, the RET protooncogene appears to be the predominant driver mutation for oncogenesis. The German S3 thyroid carcinoma guidelines recommend molecular genetic analysis of the tumour without specifying the site of the tissue sampling. Whether there is difference in RET protooncogene between the primary tumour, lymph node, and distant metastasis has not yet been investigated. However, differences could be important with regard to biopsy localization, and also, thus, the choice of single- or multi-tyrosine-kinase-inhibitor therapy. Methods: In a case of sporadic MTC, Cancer Hotspot panel diagnostics were performed on the primary tumour, lymph node metastasis, and distant metastasis. Mutations were classified using different gene databases, and the different stages of metastasis were compared. Results: RET protooncogene (chr10:43609933, c.1886_1891delTGTGCG, p.Leu629_Asp631delinsHis) was found to be present in the MTC tissue of the primary tumour, lymph node, and distant metastasis in the Cancer Hotspot Panel diagnostic, while the other investigated therapy-relevant mutational profiles were not consistently found. Conclusions: Further longitudinal studies in larger patient cohorts are required to elucidate the role of the RET protooncogene in the metastatic progression of MTC and to determine its impact on the selection of biopsy sites and the subsequent decision-making regarding single- versus multi-tyrosine kinase inhibitor therapy.
- 18 July 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (7) , 560
Open AccessNext-Generation Sequencing Reveals the Potential Role of RET Protooncogene in Metastasis Progression in Medullary Thyroid Cancer
Background: Medullary thyroid carcinoma (MTC) has a high rate of local and distant metastases. In particular, the RET protooncogene appears to be the predominant driver mutation for oncogenesis. The German S3 thyroid carcinoma guidelines recommend molecular genetic analysis of the tumour without specifying the site of the tissue sampling. Whether there is difference in RET protooncogene between the primary tumour, lymph node, and distant metastasis has not yet been investigated. However, differences could be important with regard to biopsy localization, and also, thus, the choice of single- or multi-tyrosine-kinase-inhibitor therapy. Methods: In a case of sporadic MTC, Cancer Hotspot panel diagnostics were performed on the primary tumour, lymph node metastasis, and distant metastasis. Mutations were classified using different gene databases, and the different stages of metastasis were compared. Results: RET protooncogene (chr10:43609933, c.1886_1891delTGTGCG, p.Leu629_Asp631delinsHis) was found to be present in the MTC tissue of the primary tumour, lymph node, and distant metastasis in the Cancer Hotspot Panel diagnostic, while the other investigated therapy-relevant mutational profiles were not consistently found. Conclusions: Further longitudinal studies in larger patient cohorts are required to elucidate the role of the RET protooncogene in the metastatic progression of MTC and to determine its impact on the selection of biopsy sites and the subsequent decision-making regarding single- versus multi-tyrosine kinase inhibitor therapy.
- 23 January 2025
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 29 (1) , 1-14
Microvascular reconstruction in oral and maxillofacial surgery: a Europe-wide data collection
Purpose This study aims to analyze microvascular reconstruction in Oral and Maxillofacial Surgery (OMFS) in Europe. Methods Based on previous studies, a dynamic online questionnaire was developed and subjected to internal and external evaluation. The questionnaire comprised multiple-choice, rating, and open-ended questions, addressing general and specific aspects and the impacts of the COVID-19 pandemic on microvascular reconstruction in OMFS in Europe. It was implemented into SurveyMonkey’s® online survey software and emailed to OMFS departments registered with the European Association for Cranio-Maxillofacial Surgery (EACMFS). Results Seventy-five participants from 23 European countries participated. Among them, 89% perform between 1 and 70 microvascular free flaps (MFF) annually. 38% of the participants reported a reduction in MFF due to the COVID-19 pandemic. The radial forearm (41% of participants) and fibula free flap (31%) are the most reported MFF. In most cases (59%), MFF procedures are exclusively performed by OMFS for OMFS patients, while 43% of participants reported cooperations with plastic surgeons to perform MFF for OMFS patients. Many participants prefer arterial end-to-end anastomoses (54%) using the facial artery (54%) and, if available, two venous anastomoses (68%). Low molecular weight heparin is the most used postoperative anticoagulant, reported by 67% of participants. For flap monitoring, clinical assessment and Doppler ultrasound are preferred by most participants (95% and 78%, respectively). Many participants (66%) indicated that tracheotomy is only performed when necessary. Differences were observed in relation to CAD/CAM (Computer-Aided Design/Computer-Aided Manufacturing) techniques, types of osteosynthesis, and dental implant treatment. Conclusion This study highlighted variability in microvascular reconstruction in OMFS in Europe. Further studies are needed to assess these aspects in detail.
- 23 January 2025
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 29 (1) , 1-14
Microvascular reconstruction in oral and maxillofacial surgery: a Europe-wide data collection
Purpose This study aims to analyze microvascular reconstruction in Oral and Maxillofacial Surgery (OMFS) in Europe. Methods Based on previous studies, a dynamic online questionnaire was developed and subjected to internal and external evaluation. The questionnaire comprised multiple-choice, rating, and open-ended questions, addressing general and specific aspects and the impacts of the COVID-19 pandemic on microvascular reconstruction in OMFS in Europe. It was implemented into SurveyMonkey’s® online survey software and emailed to OMFS departments registered with the European Association for Cranio-Maxillofacial Surgery (EACMFS). Results Seventy-five participants from 23 European countries participated. Among them, 89% perform between 1 and 70 microvascular free flaps (MFF) annually. 38% of the participants reported a reduction in MFF due to the COVID-19 pandemic. The radial forearm (41% of participants) and fibula free flap (31%) are the most reported MFF. In most cases (59%), MFF procedures are exclusively performed by OMFS for OMFS patients, while 43% of participants reported cooperations with plastic surgeons to perform MFF for OMFS patients. Many participants prefer arterial end-to-end anastomoses (54%) using the facial artery (54%) and, if available, two venous anastomoses (68%). Low molecular weight heparin is the most used postoperative anticoagulant, reported by 67% of participants. For flap monitoring, clinical assessment and Doppler ultrasound are preferred by most participants (95% and 78%, respectively). Many participants (66%) indicated that tracheotomy is only performed when necessary. Differences were observed in relation to CAD/CAM (Computer-Aided Design/Computer-Aided Manufacturing) techniques, types of osteosynthesis, and dental implant treatment. Conclusion This study highlighted variability in microvascular reconstruction in OMFS in Europe. Further studies are needed to assess these aspects in detail.